ep0042

EP0042 is an orally available, dual inhibitor of FLT3 (Fms-like tyrosine kinase 3) and Aurora kinase, developed primarily for the treatment of acute myeloid leukemia (AML), particularly in patients who have developed resistance to prior FLT3 inhibitors. The drug targets two key pathways involved in leukemic cell proliferation and survival—FLT3 mutations are associated with poor prognosis and high relapse rates in AML, while Aurora kinases are critical for cell division. By inhibiting both targets, EP0042 aims to overcome acquired resistance mechanisms seen with current FLT3 inhibitors. It is being evaluated as monotherapy and in combination with other anti-cancer agents such as venetoclax. EP0042 has received Orphan Drug Designation from the US FDA for AML and is currently undergoing Phase 1/2 clinical trials in relapsed/refractory AML, chronic myelomonocytic leukemia (CMML), and myelodysplastic syndrome (MDS). Early data indicate a manageable safety profile with promising activity in heavily pretreated patients[1][2][5][6][7].

Other names

dual FLT3 and Aurora kinase inhibitor